MENY

Gällande vårdprogram äggstockscancer

Fastställd av Regionala cancercentrum i samverkan 2015-06-04

21. Referenser

    1. Socialstyrelsen. Cancerincidens i Sverige 2012. Stockholm. (Hämtad 2014-01-20).
    2. Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. European journal of cancer. 2004;40(15):2307-16.
    3. Socialstyrelsen. Cancer i Sverige. Insjuknande och överlevnad utifrån regional och socioekonomisk indelning. Artikelnr 2011-3-26. Publicerad, mars 2011.
    4. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. The Lancet Oncology. 2014;15(1):23-34.
    5. Akeson M, Jakobsen AM, Zetterqvist BM, Holmberg E, Brannstrom M, Horvath G. A population-based 5-year cohort study including all cases of epithelial ovarian cancer in western Sweden: 10-year survival and prognostic factors. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009;19(1):116-23.
    6. Akeson M, Zetterqvist BM, Dahllof K, Brannstrom M, Horvath G. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up. Acta obstetricia et gynecologica Scandinavica. 2008;87(12):1343-52.
    7. Weiderpass E, Oh JK, Algeri S, Bellocco R. Socioeconomic status and epithelial ovarian cancer survival in Sweden. Cancer causes & control : CCC. 2014;25(8):1063-73.
    8. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(25):3985-90.
    9. Przybycin CG, Kurman RJ, Ronnett BM, Shih Ie M, Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin? The American journal of surgical pathology. 2010;34(10):1407-16.
    10. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. The Journal of pathology. 2010;221(1):49-56.
    11. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-15.
    12. Martinek I, Haldar K, Gaitskell K, Bryant A, Nicum S, Kehoe S, et al. DNA-repair pathway inhibitors for the treatment of ovarian cancer. The Cochrane database of systematic reviews. 2010(6):CD007929.
    13. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43(5):420-32.
    14. Anglesio MS, Carey MS, Kobel M, Mackay H, Huntsman DG, Vancouver Ovarian Clear Cell Symposium S. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecologic oncology. 2011;121(2):407-15.
    15. Brown J, Frumovitz M. Mucinous tumors of the ovary: current thoughts on diagnosis and management. Current oncology reports. 2014;16(6):389.
    16. Anglesio MS, Kommoss S, Tolcher MC, Clarke B, Galletta L, Porter H, et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. The Journal of pathology. 2013;229(1):111-20.
    17. Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013;24 Suppl 10:x16-21.
    18. Purdie DM, Bain CJ, Siskind V, Webb PM, Green AC. Ovulation and risk of epithelial ovarian cancer. International journal of cancer Journal international du cancer. 2003;104(2):228-32.
    19. Negri E, Pelucchi C, Franceschi S, Montella M, Conti E, Dal Maso L, et al. Family history of cancer and risk of ovarian cancer. European journal of cancer. 2003;39(4):505-10.
    20. Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer. Molecular oncology. 2009;3(2):138-50.
    21. Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America. 2011;108(44):18032-7.
    22. Watson P, Vasen HF, Mecklin JP, Bernstein I, Aarnio M, Jarvinen HJ, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. International journal of cancer Journal international du cancer. 2008;123(2):444-9.
    23. Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nature reviews Cancer. 2010;10(11):803-8.
    24. Charbonneau B, Block MS, Bamlet WR, Vierkant RA, Kalli KR, Fogarty Z, et al. Risk of ovarian cancer and the NF-kappaB pathway: genetic association with IL1A and TNFSF10. Cancer research. 2014;74(3):852-61.
    25. Greiser CM, Greiser EM, Doren M. Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Human reproduction update. 2007;13(5):453-63.
    26. Zhou B, Sun Q, Cong R, Gu H, Tang N, Yang L, et al. Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecologic oncology. 2008;108(3):641-51.
    27. Pearce CL, Chung K, Pike MC, Wu AH. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer. 2009;115(3):531-9.
    28. Beral V, Million Women Study C, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet. 2007;369(9574):1703-10.
    29. Morch LS, Lokkegaard E, Andreasen AH, Kruger-Kjaer S, Lidegaard O. Hormone therapy and ovarian cancer. Jama. 2009;302(3):298-305.
    30. Jensen A, Sharif H, Olsen JH, Kjaer SK. Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. American journal of epidemiology. 2008;168(1):49-57.
    31. Tworoger SS, Fairfield KM, Colditz GA, Rosner BA, Hankinson SE. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. American journal of epidemiology. 2007;166(8):894-901.
    32. van Leeuwen FE, Klip H, Mooij TM, van de Swaluw AM, Lambalk CB, Kortman M, et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Human reproduction. 2011;26(12):3456-65.
    33. Rizzuto I, Behrens RF, Smith LA. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. The Cochrane database of systematic reviews. 2013;8:CD008215.
    34. Nezhat F, Datta MS, Hanson V, Pejovic T, Nezhat C, Nezhat C. The relationship of endometriosis and ovarian malignancy: a review. Fertility and sterility. 2008;90(5):1559-70.
    35. Melin A, Sparen P, Bergqvist A. The risk of cancer and the role of parity among women with endometriosis. Human reproduction. 2007;22(11):3021-6.
    36. Davis M, Rauh-Hain JA, Andrade C, Boruta DM, 2nd, Schorge JO, Horowitz NS, et al. Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary. Gynecologic oncology. 2014;132(3):760-6.
    37. Wu AH, Pearce CL, Tseng CC, Templeman C, Pike MC. Markers of inflammation and risk of ovarian cancer in Los Angeles County. International journal of cancer Journal international du cancer. 2009;124(6):1409-15.
    38. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. American journal of epidemiology. 1992;136(10):1184-203.
    39. Adami HO, Hsieh CC, Lambe M, Trichopoulos D, Leon D, Persson I, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet. 1994;344(8932):1250-4.
    40. Sueblinvong T, Carney ME. Current understanding of risk factors for ovarian cancer. Current treatment options in oncology. 2009;10(1-2):67-81.
    41. Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clinical obstetrics and gynecology. 2012;55(1):3-23.
    42. Chiaffarino F, Pelucchi C, Negri E, Parazzini F, Franceschi S, Talamini R, et al. Breastfeeding and the risk of epithelial ovarian cancer in an Italian population. Gynecologic oncology. 2005;98(2):304-8.
    43. Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA, Hankinson SE. Breastfeeding and risk of ovarian cancer in two prospective cohorts. Cancer causes & control : CCC. 2007;18(5):517-23.
    44. Luan NN, Wu QJ, Gong TT, Vogtmann E, Wang YL, Lin B. Breastfeeding and ovarian cancer risk: a meta-analysis of epidemiologic studies. The American journal of clinical nutrition. 2013;98(4):1020-31.
    45. Jordan SJ, Siskind V, A CG, Whiteman DC, Webb PM. Breastfeeding and risk of epithelial ovarian cancer. Cancer causes & control : CCC. 2010;21(1):109-16.
    46. Collaborative Group on Epidemiological Studies of Ovarian C, Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet. 2008;371(9609):303-14.
    47. McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. The Lancet Oncology. 2007;8(1):26-34.
    48. Havrilesky LJ, Gierisch JM, Moorman PG, Coeytaux RR, Urrutia RP, Lowery WJ, et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evidence report/technology assessment. 2013(212):1-514.
    49. Kjaer SK, Mellemkjaer L, Brinton LA, Johansen C, Gridley G, Olsen JH. Tubal sterilization and risk of ovarian, endometrial and cervical cancer. A Danish population-based follow-up study of more than 65 000 sterilized women. International journal of epidemiology. 2004;33(3):596-602.
    50. Sieh W, Salvador S, McGuire V, Weber RP, Terry KL, Rossing MA, et al. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. International journal of epidemiology. 2013;42(2):579-89.
    51. Falconer H, Yin L, Grönberg H, Altman D. Ovarian cancer risk after salpingectomy: a nationwide population-based study. IGCS 2014 Melbourne.
    52. Rice MS, Murphy MA, Vitonis AF, Cramer DW, Titus LJ, Tworoger SS, et al. Tubal ligation, hysterectomy and epithelial ovarian cancer in the New England Case-Control Study. International journal of cancer Journal international du cancer. 2013;133(10):2415-21.
    53. McAlpine JN, Hanley GE, Woo MM, Tone AA, Rozenberg N, Swenerton KD, et al. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. American journal of obstetrics and gynecology. 2014;210(5):471 e1-11.
    54. Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM. Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. British journal of cancer. 2008;98(11):1781-3.
    55. Baandrup L, Faber MT, Christensen J, Jensen A, Andersen KK, Friis S, et al. Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. Acta obstetricia et gynecologica Scandinavica. 2013;92(3):245-55.
    56. Prentice RL, Thomson CA, Caan B, Hubbell FA, Anderson GL, Beresford SA, et al. Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. Journal of the National Cancer Institute. 2007;99(20):1534-43.
    57. Crane TE, Khulpateea BR, Alberts DS, Basen-Engquist K, Thomson CA. Dietary intake and ovarian cancer risk: a systematic review. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2014;23(2):255-73.
    58. Merritt MA, Cramer DW, Missmer SA, Vitonis AF, Titus LJ, Terry KL. Dietary fat intake and risk of epithelial ovarian cancer by tumour histology. British journal of cancer. 2014;110(5):1392-401.
    59. Prescott J, Bertrand KA, Poole EM, Rosner BA, Tworoger SS. Surrogates of long-term vitamin d exposure and ovarian cancer risk in two prospective cohort studies. Cancers. 2013;5(4):1577-600.
    60. Redaniel MT, Gardner MP, Martin RM, Jeffreys M. The association of vitamin D supplementation with the risk of cancer in postmenopausal women. Cancer causes & control : CCC. 2014;25(2):267-71.
    61. Olsen CM, Bain CJ, Jordan SJ, Nagle CM, Green AC, Whiteman DC, et al. Recreational physical activity and epithelial ovarian cancer: a case-control study, systematic review, and meta-analysis. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2007;16(11):2321-30.
    62. Xiao Q, Yang HP, Wentzensen N, Hollenbeck A, Matthews CE. Physical activity in different periods of life, sedentary behavior, and the risk of ovarian cancer in the NIH-AARP diet and health study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2013;22(11):2000-8.
    63. Schouten LJ, Rivera C, Hunter DJ, Spiegelman D, Adami HO, Arslan A, et al. Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2008;17(4):902-12.
    64. Olsen CM, Nagle CM, Whiteman DC, Ness R, Pearce CL, Pike MC, et al. Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocrine-related cancer. 2013;20(2):251-62.
    65. Jordan SJ, Whiteman DC, Purdie DM, Green AC, Webb PM. Does smoking increase risk of ovarian cancer? A systematic review. Gynecologic oncology. 2006;103(3):1122-9.
    66. Rota M, Pasquali E, Scotti L, Pelucchi C, Tramacere I, Islami F, et al. Alcohol drinking and epithelial ovarian cancer risk. a systematic review and meta-analysis. Gynecologic oncology. 2012;125(3):758-63.
    67.  Pharoah PD, Ponder BA. The genetics of ovarian cancer. Best practice & research Clinical obstetrics & gynaecology. 2002;16(4):449-68.
    68. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. The New England journal of medicine. 2002;346(21):1609-15.
    69. Prat J, Ribe A, Gallardo A. Hereditary ovarian cancer. Human pathology. 2005;36(8):861-70.
    70. Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. Journal of the National Cancer Institute. 1997;89(3):227-38.
    71. Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. American journal of human genetics. 1998;62(1):145-58.
    72. Daniels MS, Babb SA, King RH, Urbauer DL, Batte BA, Brandt AC, et al. Underestimation of risk of a BRCA1 or BRCA2 mutation in women with high-grade serous ovarian cancer by BRCAPRO: a multi-institution study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(12):1249-55.
    73. Mutch D, Denny L, Quinn M, Oncology FCoG. Hereditary gynecologic cancers. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2014;124(3):189-92.
    74. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nature genetics. 1996;12(3):333-7.
    75. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. American journal of human genetics. 2001;68(3):700-10.
    76. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. American journal of human genetics. 2003;72(5):1117-30.
    77. Thompson D, Easton DF, Breast Cancer Linkage C. Cancer Incidence in BRCA1 mutation carriers. Journal of the National Cancer Institute. 2002;94(18):1358-65.
    78. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(21):2654-63.
    79. Werness BA, Ramus SJ, Whittemore AS, Garlinghouse-Jones K, Oakley-Girvan I, Dicioccio RA, et al. Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Human pathology. 2000;31(11):1420-4.
    80. Gotlieb WH, Chetrit A, Menczer J, Hirsh-Yechezkel G, Lubin F, Friedman E, et al. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gynecologic oncology. 2005;97(3):780-3.
    81. Bolton KL, Chenevix-Trench G, Goh C, Sadetzki S, Ramus SJ, Karlan BY, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. Jama. 2012;307(4):382-90.
    82. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England journal of medicine. 2009;361(2):123-34.
    83. Aarnio M, Mecklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. International journal of cancer Journal international du cancer. 1995;64(6):430-3.
    84. Watson P, Butzow R, Lynch HT, Mecklin JP, Jarvinen HJ, Vasen HF, et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecologic oncology. 2001;82(2):223-8.
    85. Pal T, Permuth-Wey J, Kumar A, Sellers TA. Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008;14(21):6847-54.
    86. Ketabi Z, Bartuma K, Bernstein I, Malander S, Gronberg H, Bjorck E, et al. Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors. Gynecologic oncology. 2011;121(3):462-5.
    87. Woods MO, Williams P, Careen A, Edwards L, Bartlett S, McLaughlin JR, et al. A new variant database for mismatch repair genes associated with Lynch syndrome. Human mutation. 2007;28(7):669-73.
    88. Antoniou AC, Gayther SA, Stratton JF, Ponder BA, Easton DF. Risk models for familial ovarian and breast cancer. Genetic epidemiology. 2000;18(2):173-90.
    89. Erkko H, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A, et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007;446(7133):316-9.
    90. Soegaard M, Jensen A, Hogdall E, Christensen L, Hogdall C, Blaakaer J, et al. Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2007;16(6):1160-6.
    91. Gaarenstroom KN, van der Hiel B, Tollenaar RA, Vink GR, Jansen FW, van Asperen CJ, et al. Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2006;16 Suppl 1:54-9.
    92. van der Velde NM, Mourits MJ, Arts HJ, de Vries J, Leegte BK, Dijkhuis G, et al. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? International journal of cancer Journal international du cancer. 2009;124(4):919-23.
    93. Schenberg T, Mitchell G. Prophylactic bilateral salpingectomy as a prevention strategy in women at high-risk of ovarian cancer: a mini-review. Frontiers in oncology. 2014;4:21.
    94. Renkonen-Sinisalo L, Butzow R, Leminen A, Lehtovirta P, Mecklin JP, Jarvinen HJ. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. International journal of cancer Journal international du cancer. 2007;120(4):821-4.
    95. Auranen A, Joutsiniemi T. A systematic review of gynecological cancer surveillance in women belonging to hereditary nonpolyposis colorectal cancer (Lynch syndrome) families. Acta obstetricia et gynecologica Scandinavica. 2011;90(5):437-44.
    96. Finch AP, Lubinski J, Moller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(15):1547-53.
    97. Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecologic oncology. 2005;97(2):457-67.
    98. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. Jama. 2010;304(9):967-75.
    99. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. The New England journal of medicine. 2002;346(21):1616-22.
    100. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(30):7491-6.
    101. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(31):7804-10.
    102. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. The New England journal of medicine. 2006;354(3):261-9.
    103. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. Journal of the National Cancer Institute. 1999;91(17):1475-9.
    104. Parker WH, Broder MS, Liu Z, Shoupe D, Farquhar C, Berek JS. Ovarian conservation at the time of hysterectomy for benign disease. Clinical obstetrics and gynecology. 2007;50(2):354-61.
    105. Cohen JV, Chiel L, Boghossian L, Jones M, Stopfer JE, Powers J, et al. Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy. Familial cancer. 2012;11(1):69-75.
    106. Whittemore AS, Balise RR, Pharoah PD, Dicioccio RA, Oakley-Girvan I, Ramus SJ, et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. British journal of cancer. 2004;91(11):1911-5.
    107. Iodice S, Barile M, Rotmensz N, Feroce I, Bonanni B, Radice P, et al. Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. European journal of cancer. 2010;46(12):2275-84.
    108. Brohet RM, Goldgar DE, Easton DF, Antoniou AC, Andrieu N, Chang-Claude J, et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(25):3831-6.
    109. Cibula D, Zikan M, Dusek L, Majek O. Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert review of anticancer therapy. 2011;11(8):1197-207.
    110. Pinsky PF, Zhu C, Skates SJ, Black A, Partridge E, Buys SS, et al. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial. International journal of cancer Journal international du cancer. 2013;132(9):2127-33.
    111. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). The Lancet Oncology. 2009;10(4):327-40.
    112. Reade CJ, Riva JJ, Busse JW, Goldsmith CH, Elit L. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecologic oncology. 2013;130(3):674-81.
    113. Nolen BM, Lokshin AE. Biomarker testing for ovarian cancer: clinical utility of multiplex assays. Molecular diagnosis & therapy. 2013;17(3):139-46.
    114. Zhang Z, Chan DW. The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010;19(12):2995-9.
    115. Mai PL, Wentzensen N, Greene MH. Challenges related to developing serum-based biomarkers for early ovarian cancer detection. Cancer prevention research. 2011;4(3):303-6.
    116. Rosenthal AN. Ovarian cancer screening in the high-risk population--the UK Familial Ovarian Cancer Screening Study (UKFOCSS). International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2012;22 Suppl 1:S27-8.
    117. Rosenthal AN, Fraser L, Manchanda R, Badman P, Philpott S, Mozersky J, et al. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(1):49-57.
    118. Bankhead CR, Collins C, Stokes-Lampard H, Rose P, Wilson S, Clements A, et al. Identifying symptoms of ovarian cancer: a qualitative and quantitative study. BJOG : an international journal of obstetrics and gynaecology. 2008;115(8):1008-14.
    119. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer. 2000;89(10):2068-75.
    120. Bankhead CR, Kehoe ST, Austoker J. Symptoms associated with diagnosis of ovarian cancer: a systematic review. BJOG : an international journal of obstetrics and gynaecology. 2005;112(7):857-65.
    121. Hamilton W, Peters TJ, Bankhead C, Sharp D. Risk of ovarian cancer in women with symptoms in primary care: population based case-control study. Bmj. 2009;339:b2998.
    122. Rossing MA, Wicklund KG, Cushing-Haugen KL, Weiss NS. Predictive value of symptoms for early detection of ovarian cancer. Journal of the National Cancer Institute. 2010;102(4):222-9.
    123. NICE clinical guideline. Ovarian cancer: the recognition and initial management of ovarian cancer. Full guideline april 2011. Published by the National Collaborating Centre for Cancer at Velindre NHS Trust, Cardiff, Wales. ISBN 978-0-9558265-5-9.
    124. Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer. 2007;109(2):221-7.
    125. Morice P, Joulie F, Camatte S, Atallah D, Rouzier R, Pautier P, et al. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. Journal of the American College of Surgeons. 2003;197(2):198-205
    126. Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E, Tekkis PP. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surgical oncology. 2009;18(1):15-24.
    127. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. British journal of obstetrics and gynaecology. 1990;97(10):922-9.
    128. Tingulstad S, Hagen B, Skjeldestad FE, Onsrud M, Kiserud T, Halvorsen T, et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. British journal of obstetrics and gynaecology. 1996;103(8):826-31.
    129. Geomini P, Kruitwagen R, Bremer GL, Cnossen J, Mol BW. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstetrics and gynecology. 2009;113(2 Pt 1):384-94.
    130. Fung ET. A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clinical chemistry. 2010;56(2):327-9.
    131. Zhang Z. An In Vitro Diagnostic Multivariate Index Assay (IVDMIA) for Ovarian Cancer: Harvesting the Power of Multiple Biomarkers. Reviews in obstetrics & gynecology. 2012;5(1):35-41.
    132. Ueland FR, Desimone CP, Seamon LG, Miller RA, Goodrich S, Podzielinski I, et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstetrics and gynecology. 2011;117(6):1289-97.
    133. Longoria TC, Ueland FR, Zhang Z, Chan DW, Smith A, Fung ET, et al. Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer. American journal of obstetrics and gynecology. 2014;210(1):78 e1-9.
    134. Geerts I, Vergote I, Neven P, Billen J. The role of inhibins B and antimullerian hormone for diagnosis and follow-up of granulosa cell tumors. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009;19(5):847-55.
    135. Griffiths P, Richardson A, Blackwell R. Outcomes sensitive to nursing service quality in ambulatory cancer chemotherapy: Systematic scoping review. European journal of oncology nursing : the official journal of European Oncology Nursing Society. 2012;16(3):238-46.
    136. Spencer JA, Swift SE, Wilkinson N, Boon AP, Lane G, Perren TJ. Peritoneal carcinomatosis: image-guided peritoneal core biopsy for tumor type and patient care. Radiology. 2001;221(1):173-7.
    137. Spencer JA, Weston MJ, Saidi SA, Wilkinson N, Hall GD. Clinical utility of image-guided peritoneal and omental biopsy. Nature reviews Clinical oncology. 2010;7(11):623-31.
    138. Bharwani N, Reznek RH, Rockall AG. Ovarian Cancer Management: the role of imaging and diagnostic challenges. European journal of radiology. 2011;78(1):41-51.
    139. Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet. 2001;357(9251):176-82.
    140. Valentin L, Ameye L, Savelli L, Fruscio R, Leone FP, Czekierdowski A, et al. Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2011;38(4):456-65.
    141. Timmerman D, Testa AC, Bourne T, Ferrazzi E, Ameye L, Konstantinovic ML, et al. Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(34):8794-801.
    142. Timmerman D, Ameye L, Fischerova D, Epstein E, Melis GB, Guerriero S, et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. Bmj. 2010;341:c6839.
    143. Ameye L, Timmerman D, Valentin L, Paladini D, Zhang J, Van Holsbeke C, et al. Clinically oriented three-step strategy for assessment of adnexal pathology. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2012;40(5):582-91.
    144. Sayasneh A, Wynants L, Preisler J, Kaijser J, Johnson S, Stalder C, et al. Multicentre external validation of IOTA prediction models and RMI by operators with varied training. British journal of cancer. 2013;108(12):2448-54.
    145. Timmers PJ, Zwinderman K, Coens C, Vergote I, Trimbos JB. Lymph node sampling and taking of blind biopsies are important elements of the surgical staging of early ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2010;20(7):1142-7.
    146. Valentin L, Skoog L, Epstein E. Frequency and type of adnexal lesions in autopsy material from postmenopausal women: ultrasound study with histological correlation. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2003;22(3):284-9.
    147. Zikan M, Fischerova D, Pinkavova I, Dundr P, Cibula D. Ultrasound-guided tru-cut biopsy of abdominal and pelvic tumors in gynecology. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2010;36(6):767-72.
    148. Griffin N, Grant LA, Sala E. Adnexal masses: characterization and imaging strategies. Seminars in ultrasound, CT, and MR. 2010;31(5):330-46.
    149. Medeiros LR, Freitas LB, Rosa DD, Silva FR, Silva LS, Birtencourt LT, et al. Accuracy of magnetic resonance imaging in ovarian tumor: a systematic quantitative review. American journal of obstetrics and gynecology. 2011;204(1):67 e1-10.
    150. Thomassin-Naggara I, Darai E, Cuenod CA, Fournier L, Toussaint I, Marsault C, et al. Contribution of diffusion-weighted MR imaging for predicting benignity of complex adnexal masses. European radiology. 2009;19(6):1544-52.
    151. Moyle P, Addley HC, Sala E. Radiological staging of ovarian carcinoma. Seminars in ultrasound, CT, and MR. 2010;31(5):388-98.
    152. Kyriazi S, Collins DJ, Messiou C, Pennert K, Davidson RL, Giles SL, et al. Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging--value of histogram analysis of apparent diffusion coefficients. Radiology. 2011;261(1):182-92.
    153. Yuan Y, Gu ZX, Tao XF, Liu SY. Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: a meta-analysis. European journal of radiology. 2012;81(5):1002-6.
    154. Nam EJ, Yun MJ, Oh YT, Kim JW, Kim JH, Kim S, et al. Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. Gynecologic oncology. 2010;116(3):389-94.
    155. Risum S, Hogdall C, Loft A, Berthelsen AK, Hogdall E, Nedergaard L, et al. Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer? Gynecologic oncology. 2010;116(3):395-8.
    156. Risum S, Hogdall C, Loft A, Berthelsen AK, Hogdall E, Nedergaard L, et al. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography--a prospective study. Gynecologic oncology. 2008;108(2):265-70.
    157. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer. 2009;45(2):228-47.
    158. Pados G, Tsolakidis D, Bontis J. Laparoscopic management of the adnexal mass. Annals of the New York Academy of Sciences. 2006;1092:211-28.
    159. Spencer JA, Forstner R, Cunha TM, Kinkel K, Sub-Committee EFI. ESUR guidelines for MR imaging of the sonographically indeterminate adnexal mass: an algorithmic approach. European radiology. 2010;20(1):25-35.
    160. Acs G. Intraoperative consultation in gynecologic pathology. Seminars in diagnostic pathology. 2002;19(4):237-54.
    161. Akrivos N, Thomakos N, Sotiropoulou M, Rodolakis A, Antsaklis A. Intraoperative consultation in ovarian pathology. Gynecologic and obstetric investigation. 2010;70(3):193-9.
    162. Cross PA, Naik R, Patel A, Nayar AG, Hemming JD, Williamson SL, et al. Intra-operative frozen section analysis for suspected early-stage ovarian cancer: 11 years of Gateshead Cancer Centre experience. BJOG : an international journal of obstetrics and gynaecology. 2012;119(2):194-201.
    163. Shih KK, Garg K, Soslow RA, Chi DS, Abu-Rustum NR, Barakat RR. Accuracy of frozen section diagnosis of ovarian borderline tumor. Gynecologic oncology. 2011;123(3):517-21.
    164. Bige O, Demir A, Saygili U, Gode F, Uslu T, Koyuncuoglu M. Frozen section diagnoses of 578 ovarian tumors made by pathologists with and without expertise on gynecologic pathology. Gynecologic oncology. 2011;123(1):43-6.
    165. Jones CM, Ashrafian H, Darzi A, Athanasiou T. Guidelines for diagnostic tests and diagnostic accuracy in surgical research. Journal of investigative surgery : the official journal of the Academy of Surgical Research. 2010;23(1):57-65.
    166. Hayes DF, Bast RC, Desch CE, Fritsche H, Jr., Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. Journal of the National Cancer Institute. 1996;88(20):1456-66.
    167. Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2005;15(5):679-91.
    168. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clinical chemistry. 2008;54(12):e11-79.
    169. Tuxen MK, Soletormos G, Rustin GJ, Nelstrop AE, Dombernowsky P. Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer. Scandinavian journal of clinical and laboratory investigation. 2000;60(8):713-21.
    170. Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pacific journal of cancer prevention : APJCP. 2010;11(1):111-6.
    171. Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. British journal of cancer. 2009;100(8):1315-9.
    172. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecologic oncology. 2008;108(2):402-8.
    173. Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC, Jr., et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecologic oncology. 2010;117(3):440-5.
    174. Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2009;18(5):1365-72.
    175. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic oncology. 2009;112(1):40-6.
    176. Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. British journal of cancer. 2011;104(5):863-70.
    177. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. American journal of obstetrics and gynecology. 2010;203(3):228 e1-6.
    178. NICE clinical guidelines nr 122; ovarian cancer: the recognition and initial management of ovarian cancer 2011.
    179. Keshaviah A, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D, Collins J, et al. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2007;18(4):701-8.
    180. Kurman RJ, Carcangiu ML, Herrington CS, Young RH, eds. World Health Organization classification of Tumours of female reproductive organs Lyon: IARC Press; 2014. ISBN 978-92-832-2435-8. .
    181. Kurman RJ, Ellenson LH, Ronnett BM eds.: Blaustein’s Pathology of the Female Genital Tract. 6th edition. Springer Verlag 2011. ISBN: 978-1-4419-0488-1.
    182. Lee Y, Medeiros F, Kindelberger D, Callahan MJ, Muto MG, Crum CP. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Advances in anatomic pathology. 2006;13(1):1-7.
    183. Rabban JT, Krasik E, Chen LM, Powell CB, Crawford B, Zaloudek CJ. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. The American journal of surgical pathology. 2009;33(12):1878-85.
    184. Usubutun A, Ozseker HS, Himmetoglu C, Balci S, Ayhan A. Omentectomy for gynecologic cancer: how much sampling is adequate for microscopic examination? Archives of pathology & laboratory medicine. 2007;131(10):1578-81.
    185. Niemann TH, Yilmaz AG, Marsh WL, Jr., Lucas JG. A half a node or a whole node: a comparison of methods for submitting lymph nodes. American journal of clinical pathology. 1998;109(5):571-6.
    186. Nucci MR, Oliva E (eds.) Gynecologic pathology. Churchill Livingstone 2009 ISBN 978-0-443-06920-8.
    187. Prat J, De Nictolis M. Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion. The American journal of surgical pathology. 2002;26(9):1111-28.
    188. Fadare O. Recent developments on the significance and pathogenesis of lymph node involvement in ovarian serous tumors of low malignant potential (borderline tumors). International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009;19(1):103-8.
    189. Bell KA, Smith Sehdev AE, Kurman RJ. Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas. The American journal of surgical pathology. 2001;25(4):419-32.
    190. Seidman JD, Soslow RA, Vang R, Berman JJ, Stoler MH, Sherman ME, et al. Borderline ovarian tumors: diverse contemporary viewpoints on terminology and diagnostic criteria with illustrative images. Human pathology. 2004;35(8):918-33.
    191. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 2008;27(2):161-74.
    192. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 2000;19(1):7-15.
    193. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, et al. Grading ovarian serous carcinoma using a two-tier system. The American journal of surgical pathology. 2004;28(4):496-504.
    194. Malpica A, Deavers MT, Tornos C, Kurman RJ, Soslow R, Seidman JD, et al. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. The American journal of surgical pathology. 2007;31(8):1168-74.
    195. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2006;95 Suppl 1:S161-92.
    196. Prat J, Oncology FCoG. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2014;124(1):1-5.
    197. Ahmed FY, Wiltshaw E, A'Hern RP, Nicol B, Shepherd J, Blake P, et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996;14(11):2968-75.
    198. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. The New England journal of medicine. 1990;322(15):1021-7.
    199. Cliby WA, Aletti GD, Wilson TO, Podratz KC. Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only? Gynecologic oncology. 2006;103(3):797-801.
    200. Mahdi H, Thrall M, Kumar S, Hanna R, Seward S, Lockhart D, et al. The prognostic impact of the ratio of positive lymph nodes on survival of epithelial ovarian cancer patients. Journal of surgical oncology. 2011;103(7):724-9.
    201. Berek JS. Lymph node-positive stage IIIC ovarian cancer: a separate entity? International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009;19 Suppl 2:S18-20.
    202. Chan JK, Urban R, Hu JM, Shin JY, Husain A, Teng NN, et al. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients. British journal of cancer. 2007;96(12):1817-22.
    203. Pereira A, Perez-Medina T, Magrina JF, Magtibay PM, Millan I, Iglesias E. The role of lymphadenectomy in node-positive epithelial ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2012;22(6):987-92.
    204. Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. Journal of the National Cancer Institute. 2005;97(8):560-6.
    205. du Bois A, Reuss A, Harter P, Pujade-Lauraine E, Ray-Coquard I, Pfisterer J, et al. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(10):1733-9.
    206. Chan JK, Urban R, Cheung MK, Osann K, Shin JY, Husain A, et al. Ovarian cancer in younger vs older women: a population-based analysis. British journal of cancer. 2006;95(10):1314-20.
    207. Blumenfeld D, Braly PS, Ben-Ezra J, Klevecz RR. Tumor DNA content as a prognostic feature in advanced epithelial ovarian carcinoma. Gynecologic oncology. 1987;27(3):389-402.
    208. Friedlander ML, Hedley DW, Swanson C, Russell P. Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1988;6(2):282-90.
    209. Trope C, Kaern J, Hogberg T, Abeler V, Hagen B, Kristensen G, et al. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2000;11(3):281-8.
    210. Barnabei VM, Miller DS, Bauer KD, Murad TM, Rademaker AW, Lurain JR. Flow cytometric evaluation of epithelial ovarian cancer. American journal of obstetrics and gynecology. 1990;162(6):1584-90; discussion 90-2.
    211. Pfisterer J, Kommoss F, Sauerbrei W, Renz H, du Bois A, Kiechle-Schwarz M, et al. Cellular DNA content and survival in advanced ovarian carcinoma. Cancer. 1994;74(9):2509-15.
    212. Coley HM, Sargent JM, Titley J, Taylor CG. Lack of prognostic significance of ploidy and S-phase measurements in advanced ovarian cancer. Anticancer research. 1999;19(3A):2111-6.
    213. Veerman MM, van der Wurff AA, van de Water M, Kruitwagen RF, Feijen HW, Vos MC. Clinical value of morphometric and DNA flow cytometric variables as independent predictors of survival in epithelial ovarian carcinoma: a 5-year follow-up study. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 2009;28(5):432-41.
    214. Hannibal CG, Vang R, Junge J, Kjaerbye-Thygesen A, Kurman RJ, Kjaer SK. A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006. Gynecologic oncology. 2012;125(3):655-60.
    215. Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecologic oncology. 2008;109(3):370-6.
    216. Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H, et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. British journal of cancer. 2006;94(10):1369-74.
    217. Tan DS, Kaye S. Ovarian clear cell adenocarcinoma: a continuing enigma. Journal of clinical pathology. 2007;60(4):355-60.
    218. Harrison ML, Jameson C, Gore ME. Mucinous ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2008;18(2):209-14.
    219. Kleppe M, Wang T, Van Gorp T, Slangen BF, Kruse AJ, Kruitwagen RF. Lymph node metastasis in stages I and II ovarian cancer: a review. Gynecologic oncology. 2011;123(3):610-4.
    220. Kim HS, Ahn JH, Chung HH, Kim JW, Park NH, Song YS, et al. Impact of intraoperative rupture of the ovarian capsule on prognosis in patients with early-stage epithelial ovarian cancer: a meta-analysis. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2013;39(3):279-89.
    221. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002;20(5):1248-59.
    222. Winter WE, 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(1):83-9.
    223. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234-44.
    224. Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade-Lauraine E, Swart AM, et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2010;20(6):945-52.
    225. Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A, et al. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Annals of surgical oncology. 2010;17(6):1642-8.
    226. Sorbe B. Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2003;13 Suppl 2:192-5.
    227. Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, et al. The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecologic oncology. 2013;131(1):15-20.
    228. Mahner S, Eulenburg C, Staehle A, Wegscheider K, Reuss A, Pujade-Lauraine E, et al. Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. European journal of cancer. 2013;49(1):142-9.
    229. Sieh W, Kobel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. The Lancet Oncology. 2013;14(9):853-62.
    230. Altman DG, Lyman GH. Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast cancer research and treatment. 1998;52(1-3):289-303.
    231. Hayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast cancer research and treatment. 1998;52(1-3):305-19.
    232. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). European journal of cancer. 2005;41(12):1690-6.
    233. Horvath LE, Yordan E, Malhotra D, Leyva I, Bortel K, Schalk D, et al. Multidisciplinary care in the oncology setting: historical perspective and data from lung and gynecology multidisciplinary clinics. Journal of oncology practice / American Society of Clinical Oncology. 2010;6(6):e21-6.
    234. Gatcliffe TA, Coleman RL. Tumor board: more than treatment planning--a 1-year prospective survey. Journal of cancer education : the official journal of the American Association for Cancer Education. 2008;23(4):235-7.
    235. Greer HO, Frederick PJ, Falls NM, Tapley EB, Samples KL, Kimball KJ, et al. Impact of a weekly multidisciplinary tumor board conference on the management of women with gynecologic malignancies. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2010;20(8):1321-5.
    236. Lamb BW, Brown KF, Nagpal K, Vincent C, Green JS, Sevdalis N. Quality of care management decisions by multidisciplinary cancer teams: a systematic review. Annals of surgical oncology. 2011;18(8):2116-25.
    237. Lamb BW, Green JS, Benn J, Brown KF, Vincent CA, Sevdalis N. Improving decision making in multidisciplinary tumor boards: prospective longitudinal evaluation of a multicomponent intervention for 1,421 patients. Journal of the American College of Surgeons. 2013;217(3):412-20.
    238.  SOU 2009:11, En nationell cancerstrategi för framtiden.
    239. Lagen om ändring i hälso- och sjukvårdslagen (1982;763). SFS 2010:243.
    240. Insatser för fler kontaktsjuksköterskor inom cancervården, slutrapport 2012. (2012). Ett utvecklingsarbete inom ännu bättre cancervård. Sveriges kommuner och landsting.
    241. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. Journal of the National Cancer Institute. 2003;95(2):113-25.
    242. Maggioni A, Benedetti Panici P, Dell'Anna T, Landoni F, Lissoni A, Pellegrino A, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. British journal of cancer. 2006;95(6):699-704.
    243. Powless CA, Aletti GD, Bakkum-Gamez JN, Cliby WA. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging. Gynecologic oncology. 2011;122(3):536-40.
    244. Schilder JM, Thompson AM, DePriest PD, Ueland FR, Cibull ML, Kryscio RJ, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecologic oncology. 2002;87(1):1-7.
    245. Park JY, Kim DY, Suh DS, Kim JH, Kim YM, Kim YT, et al. Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: oncologic safety and reproductive outcomes. Gynecologic oncology. 2008;110(3):345-53.
    246. Kajiyama H, Shibata K, Mizuno M, Umezu T, Suzuki S, Nawa A, et al. Long-term survival of young women receiving fertility-sparing surgery for ovarian cancer in comparison with those undergoing radical surgery. British journal of cancer. 2011;105(9):1288-94.
    247. Satoh T, Hatae M, Watanabe Y, Yaegashi N, Ishiko O, Kodama S, et al. Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(10):1727-32.
    248. du Bois A, Heitz F, Harter P. Fertility-sparing surgery in ovarian cancer: a systematic review. Onkologie. 2013;36(7-8):436-43.
    249. Morice P, Denschlag D, Rodolakis A, Reed N, Schneider A, Kesic V, et al. Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2011;21(5):951-63.
    250. Medeiros LR, Rosa DD, Bozzetti MC, Rosa MI, Edelweiss MI, Stein AT, et al. Laparoscopy versus laparotomy for FIGO Stage I ovarian cancer. The Cochrane database of systematic reviews. 2008(4):CD005344.
    251. Colomer AT, Jimenez AM, Bover Barcelo MI. Laparoscopic treatment and staging of early ovarian cancer. Journal of minimally invasive gynecology. 2008;15(4):414-9.
    252. Jung US, Lee JH, Kyung MS, Choi JS. Feasibility and efficacy of laparoscopic management of ovarian cancer. The journal of obstetrics and gynaecology research. 2009;35(1):113-8.
    253. Nezhat FR, Ezzati M, Chuang L, Shamshirsaz AA, Rahaman J, Gretz H. Laparoscopic management of early ovarian and fallopian tube cancers: surgical and survival outcome. American journal of obstetrics and gynecology. 2009;200(1):83 e1-6.
    254. Iglesias DA, Ramirez PT. Role of minimally invasive surgery in staging of ovarian cancer. Current treatment options in oncology. 2011;12(3):217-29.
    255. Zivanovic O, Sonoda Y, Diaz JP, Levine DA, Brown CL, Chi DS, et al. The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease. Gynecologic oncology. 2008;111(3):431-7.
    256. Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecologic oncology. 2006;103(2):559-64.
    257. Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecologic oncology. 2009;114(1):26-31.
    258. du Bois A, Rochon J, Pfisterer J, Hoskins WJ. Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review. Gynecologic oncology. 2009;112(2):422-36.
    259. Sehouli J, Savvatis K, Braicu EI, Schmidt SC, Lichtenegger W, Fotopoulou C. Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2010;20(8):1331-40.
    260. Ang C, Chan KK, Bryant A, Naik R, Dickinson HO. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer. The Cochrane database of systematic reviews. 2011(4):CD007697.
    261. Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. The Cochrane database of systematic reviews. 2011(8):CD007565.
    262. Chang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecologic oncology. 2013;130(3):493-8.
    263. Harter P, Muallem ZM, Buhrmann C, Lorenz D, Kaub C, Hils R, et al. Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer. Gynecologic oncology. 2011;121(3):615-9.
    264. Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer. European journal of cancer. 2011;47 Suppl 3:S88-92.
    265. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstetrics and gynecology. 2006;107(1):77-85.
    266. Verleye L, Ottevanger PB, van der Graaf W, Reed NS, Vergote I, Gynaecological Cancer Group of European Organisation for R, et al. EORTC-GCG process quality indicators for ovarian cancer surgery. European journal of cancer. 2009;45(4):517-26.
    267. Paulsen T, Kjaerheim K, Kaern J, Tretli S, Trope C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2006;16 Suppl 1:11-7.
    268. Aune G, Torp SH, Syversen U, Hagen B, Tingulstad S. Ten years' experience with centralized surgery of ovarian cancer in one health region in Norway. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2012;22(2):226-31.
    269. Marx C, Bendixen A, Hogdall C, Ottosen C, Kehlet H, Ottesen B. Organisation and quality of primary surgical intervention for ovarian cancer in Denmark. Acta obstetricia et gynecologica Scandinavica. 2007;86(12):1496-502.
    270. Fago-Olsen CL, Hogdall C, Kehlet H, Christensen IJ, Ottesen B. Centralized treatment of advanced stages of ovarian cancer improves survival: a nationwide Danish survey. Acta obstetricia et gynecologica Scandinavica. 2011;90(3):273-9.
    271. Høgdall CK, Nielsen MLS, Taaning L. Årsrapport 2008– Dansk Gynækologisk Cancer Database. Landsdækkende klinisk database for kræft i æggestokke, livmoder og livmoderhals. ISSN 1902-7877 (papir);1903-0223 (online). København 2010. .
    272. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. The New England journal of medicine. 2010;363(10):943-53.
    273. Morrison J, Haldar K, Kehoe S, Lawrie TA. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. The Cochrane database of systematic reviews. 2012;8:CD005343.
    274. Greimel E, Kristensen GB, van der Burg ME, Coronado P, Rustin G, del Rio AS, et al. Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy. Gynecologic oncology. 2013;131(2):437-44.
    275. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecologic oncology. 2006;103(3):1070-6.
    276. Ibeanu OA, Bristow RE. Predicting the outcome of cytoreductive surgery for advanced ovarian cancer: a review. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2010;20 Suppl 1:S1-11.
    277. Rutten MJ, Leeflang MM, Kenter GG, Mol BW, Buist M. Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer. The Cochrane database of systematic reviews. 2014;2:CD009786.
    278. Tangjitgamol S, Manusirivithaya S, Laopaiboon M, Lumbiganon P, Bryant A. Interval debulking surgery for advanced epithelial ovarian cancer. The Cochrane database of systematic reviews. 2013;4:CD006014.
    279. van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. The New England journal of medicine. 1995;332(10):629-34.
    280. Rose PG, Nerenstone S, Brady MF, Clarke-Pearson D, Olt G, Rubin SC, et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. The New England journal of medicine. 2004;351(24):2489-97.
    281. Aletti GD, Santillan A, Eisenhauer EL, Hu J, Aletti G, Podratz KC, et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian cancer using a risk-adjusted model. Gynecologic oncology. 2007;107(1):99-106.
    282. Kumpulainen S, Kuoppala T, Leminen A, Penttinen J, Puistola U, Pukkala E, et al. Surgical treatment of ovarian cancer in different hospital categories--a prospective nation-wide study in Finland. European journal of cancer. 2006;42(3):388-95.
    283. Engelen MJ, Kos HE, Willemse PH, Aalders JG, de Vries EG, Schaapveld M, et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer. 2006;106(3):589-98.
    284. Vernooij F, Heintz P, Witteveen E, van der Graaf Y. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: a systematic review. Gynecologic oncology. 2007;105(3):801-12.
    285. Bristow RE, Berek JS. Surgery for ovarian cancer: how to improve survival. Lancet. 2006;367(9522):1558-60.
    286. Vernooij F, Heintz AP, Coebergh JW, Massuger LF, Witteveen PO, van der Graaf Y. Specialized and high-volume care leads to better outcomes of ovarian cancer treatment in the Netherlands. Gynecologic oncology. 2009;112(3):455-61.
    287. Bristow RE, Chang J, Ziogas A, Randall LM, Anton-Culver H. High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease. Gynecologic oncology. 2014;132(2):403-10.
    288. Cibula et al. ww.esgo.org/Education/Documents/ Training_in_Bowel_and_Upper_Abdominal_Surgery_in.99691.pdf.
    289. Tingulstad S, Skjeldestad FE, Hagen B. The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstetrics and gynecology. 2003;102(3):499-505.
    290. Kumpulainen S, Sankila R, Leminen A, Kuoppala T, Komulainen M, Puistola U, et al. The effect of hospital operative volume, residual tumor and first-line chemotherapy on survival of ovarian cancer - a prospective nation-wide study in Finland. Gynecologic oncology. 2009;115(2):199-203.
    291. Wright JD, Herzog TJ, Siddiq Z, Arend R, Neugut AI, Burke WM, et al. Failure to rescue as a source of variation in hospital mortality for ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(32):3976-82.
    292. Abu-Rustum NR, Chi DS, Sonoda Y, DiClemente MJ, Bekker G, Gemignani M, et al. Transperitoneal laparoscopic pelvic and para-aortic lymph node dissection using the argon-beam coagulator and monopolar instruments: an 8-year study and description of technique. Gynecologic oncology. 2003;89(3):504-13.
    293. Kohler C, Klemm P, Schau A, Possover M, Krause N, Tozzi R, et al. Introduction of transperitoneal lymphadenectomy in a gynecologic oncology center: analysis of 650 laparoscopic pelvic and/or paraaortic transperitoneal lymphadenectomies. Gynecologic oncology. 2004;95(1):52-61.
    294. Abu-Rustum NR, Alektiar K, Iasonos A, Lev G, Sonoda Y, Aghajanian C, et al. The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecologic oncology. 2006;103(2):714-8.
    295. Tada H, Teramukai S, Fukushima M, Sasaki H. Risk factors for lower limb lymphedema after lymph node dissection in patients with ovarian and uterine carcinoma. BMC cancer. 2009;9:47.
    296. Chi DS, Zivanovic O, Levinson KL, Kolev V, Huh J, Dottino J, et al. The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecologic oncology. 2010;119(1):38-42.
    297. Zapardiel I, Peiretti M, Zanagnolo V, Biffi R, Bocciolone L, Landoni F, et al. Diaphragmatic surgery during primary cytoreduction for advanced ovarian cancer: peritoneal stripping versus diaphragmatic resection. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2011;21(9):1698-703.
    298. Stashwick C, Post MD, Arruda JS, Spillman MA, Behbakht K, Davidson SA, et al. Surgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2011;21(8):1422-7.
    299. Obermair A, Hagenauer S, Tamandl D, Clayton RD, Nicklin JL, Perrin LC, et al. Safety and efficacy of low anterior en bloc resection as part of cytoreductive surgery for patients with ovarian cancer. Gynecologic oncology. 2001;83(1):115-20.
    300. Mourton SM, Temple LK, Abu-Rustum NR, Gemignani ML, Sonoda Y, Bochner BH, et al. Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecologic oncology. 2005;99(3):608-14.
    301. Peiretti M, Bristow RE, Zapardiel I, Gerardi M, Zanagnolo V, Biffi R, et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic oncology. 2012;126(2):220-3.
    302. Kalogera E, Dowdy SC, Mariani A, Aletti G, Bakkum-Gamez JN, Cliby WA. Utility of closed suction pelvic drains at time of large bowel resection for ovarian cancer. Gynecologic oncology. 2012;126(3):391-6.
    303. Winter-Roach BA, Kitchener HC, Lawrie TA. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. The Cochrane database of systematic reviews. 2012;3:CD004706.
    304. Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecologic oncology. 2006;102(3):432-9.
    305. Chan JK, Tian C, Fleming GF, Monk BJ, Herzog TJ, Kapp DS, et al. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecologic oncology. 2010;116(3):301-6.
    306. Travis LB, Holowaty EJ, Bergfeldt K, Lynch CF, Kohler BA, Wiklund T, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. The New England journal of medicine. 1999;340(5):351-7.
    307. Wenzel LB, Donnelly JP, Fowler JM, Habbal R, Taylor TH, Aziz N, et al. Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. Psycho-oncology. 2002;11(2):142-53.
    308. Matulonis UA, Kornblith A, Lee H, Bryan J, Gibson C, Wells C, et al. Long-term adjustment of early-stage ovarian cancer survivors. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2008;18(6):1183-93.
    309. Mirabeau-Beale KL, Kornblith AB, Penson RT, Lee H, Goodman A, Campos SM, et al. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecologic oncology. 2009;114(2):353-9.
    310. Bertelsen K, Jakobsen A, Andersen JE, Ahrons S, Pedersen PH, Kiaer H, et al. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma. Gynecologic oncology. 1987;28(2):161-9.
    311. Omura GA, Bundy BN, Berek JS, Curry S, Delgado G, Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1989;7(4):457-65.
    312. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Seminars in oncology. 1996;23(5 Suppl 12):40-7.
    313. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. Journal of the National Cancer Institute. 2000;92(9):699-708.
    314. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003;21(17):3194-200.
    315. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. Journal of the National Cancer Institute. 2003;95(17):1320-9.
    316. Collins IM, Roberts-Thomson R, Faulkner D, Rischin D, Friedlander M, Mileshkin L. Carboplatin dosing in ovarian cancer: problems and pitfalls. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2011;21(7):1213-8.
    317. Jakobsen A, Bertelsen K, Andersen JE, Havsteen H, Jakobsen P, Moeller KA, et al. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997;15(1):193-8.
    318. Gore M, Mainwaring P, A'Hern R, MacFarlane V, Slevin M, Harper P, et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998;16(7):2426-34.
    319. Kaye SB, Vasey P, Rustin G, Pledge S, Williams C, Gabra H, et al. Randomized trial of intrapatient dose escalation of single agent carboplatin as first-line treatment for advanced ovarian cancer: An SGCTG study (SCOTROC 4). J Clin Oncol 2009; 27, No 15S (May 20 Supplement), abstrakt 5537. .
    320. Hakes TB, Chalas E, Hoskins WJ, Jones WB, Markman M, Rubin SC, et al. Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecologic oncology. 1992;45(3):284-9.
    321. Bertelsen K, Jakobsen A, Stroyer J, Nielsen K, Sandberg E, Andersen JE, et al. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecologic oncology. 1993;49(1):30-6.
    322. Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A, et al. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(4):579-86.
    323. du Bois A, Herrstedt J, Hardy-Bessard AC, Muller HH, Harter P, Kristensen G, et al. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(27):4162-9.
    324. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. Journal of the National Cancer Institute. 2004;96(22):1682-91.
    325. Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(27):3628-35.
    326. du Bois A, Weber B, Rochon J, Meier W, Goupil A, Olbricht S, et al. Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(7):1127-35.
    327. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(9):1419-25.
    328. Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. Journal of the National Cancer Institute. 2006;98(15):1036-45.
    329. Hoskins P, Vergote I, Cervantes A, Tu D, Stuart G, Zola P, et al. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel. Journal of the National Cancer Institute. 2010;102(20):1547-56.
    330. Mobus V, Wandt H, Frickhofen N, Bengala C, Champion K, Kimmig R, et al. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(27):4187-93.
    331. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003;21(13):2460-5.
    332. Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. The Lancet Oncology. 2013;14(10):1020-6.
    333. Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. The Lancet Oncology. 2014;15(4):396-405.
    334. Elit L, Oliver TK, Covens A, Kwon J, Fung MF, Hirte HW, et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer. 2007;109(4):692-702.
    335. Swart AM, Burdett S, Ledermann J, Mook P, Parmar MK. Why i.p. therapy cannot yet be considered as a standard of care for the first-line treatment of ovarian cancer: a systematic review. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2008;19(4):688-95.
    336. Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. The Cochrane database of systematic reviews. 2011(11):CD005340.
    337. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. The New England journal of medicine. 2006;354(1):34-43.
    338. Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D, Gynecologic Oncology G. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(4):437-43.
    339. Gaitskell K, Martinek I, Bryant A, Kehoe S, Nicum S, Morrison J. Angiogenesis inhibitors for the treatment of ovarian cancer. The Cochrane database of systematic reviews. 2011(9):CD007930.
    340. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. The New England journal of medicine. 2011;365(26):2473-83.
    341. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. The New England journal of medicine. 2011;365(26):2484-96.
    342. Burger RA, Brady MF, Rhee J, Sovak MA, Kong G, Nguyen HP, et al. Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer. Gynecologic oncology. 2013;131(1):21-6.
    343. Oza A,  Perren TJ, Swart AM, Schröder W, Pujade-Lauraine E, Havsteen H, et al. LATE BREAKING ABSTRACT: ICON7: Final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. The European Cancer Congress 2013 (ECCO17_ESMO38_ESTRO32). Abstract number 6.
    344. TLV. Avastin (bevacizumab) Hälsoekonomiskt kunskapsunderlag. December 2013. Diarienummer: 3676/2012.
    345. NLT-gruppens yttrande till landstingen gällande bevacizumab (Avastin®). Hallberg A. 2014-06-16. Sveriges kommuner och landsting
    346. Stark D, Nankivell M, Pujade-Lauraine E, Kristensen G, Elit L, Stockler M, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. The Lancet Oncology. 2013;14(3):236-43.
    347. Monk BJ, Huang HQ, Burger RA, Mannel RS, Homesley HD, Fowler J, et al. Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study. Gynecologic oncology. 2013;128(3):573-8.
    348. du Bois A, Ewald-Riegler N, de Gregorio N, Reuss A, Mahner S, Fotopoulou C, et al. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynakologische Onkologie (AGO) Study Group. European journal of cancer. 2013;49(8):1905-14.
    349. du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(30):3374-82.
    350. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. The New England journal of medicine. 2012;366(15):1382-92.
    351. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. The Lancet Oncology. 2014;15(8):852-61.
    352. Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(4):372-9.
    353. Penson RT, Whalen C, Lasonde B, Krasner CN, Konstantinopoulos P, Stallings TE, et al. A phase II trial of iniparib (BSI-201) in combination with gemcitabine/ carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer.  J Clin Oncol 29: 2011 (suppl; abstr 5004).
    354. Harter P, Mahner S, Hilpert F, Runnebaum I, Ortmann O, Mustea A, et al. Statement by the Kommission OVAR of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer. Geburtshilfe und Frauenheilkunde. 2013;73(3):221-3.
    355. Elias A, Woodward M, Rowe CC. Management Impact of FDG-PET in Dementia: Results from a Tertiary Center Memory Clinic. Journal of Alzheimer's disease : JAD. 2014;42(3):885-92.
    356. Bijelic L, Jonson A, Sugarbaker PH. Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2007;18(12):1943-50.
    357. Cascales Campos P, Gil J, Parrilla P. Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2014;40(8):970-5.
    358. Corn BW, Lanciano RM, Boente M, Hunter WM, Ladazack J, Ozols RF. Recurrent ovarian cancer. Effective radiotherapeutic palliation after chemotherapy failure. Cancer. 1994;74(11):2979-83.
    359. Tinger A, Waldron T, Peluso N, Katin MJ, Dosoretz DE, Blitzer PH, et al. Effective palliative radiation therapy in advanced and recurrent ovarian carcinoma. International journal of radiation oncology, biology, physics. 2001;51(5):1256-63.
    360. Leffers N, Daemen T, Helfrich W, Boezen HM, Cohlen BJ, Melief K, et al. Antigen-specific active immunotherapy for ovarian cancer. The Cochrane database of systematic reviews. 2010(1):CD007287.
    361. Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(3):418-25.
    362. Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J, Jr., et al. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(17):3507-16.
    363. Pfisterer J, Berek JS, Casado A, Cwiertka K, Pinter T, Pluzanska A, et al.Randomized double-blind placebo-controlled international trial of abago-vomab maintenance therapy in patients with advanced ovarian cancer after complete response to first-line chemotherapy: The Monoclonal Antibody Immunotherapy for Malignancies of the Ovary by Subcutaneous Abago-vomab (MIMOSA) trial.J Clin Oncol 29: 2011 (suppl; abstrakt LBA5002).
    364. Kandalaft LE, Powell DJ, Jr., Singh N, Coukos G. Immunotherapy for ovarian cancer: what's next? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(7):925-33.
    365. Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 1996;7(4):361-4.
    366. Rustin GJ, Marples M, Nelstrop AE, Mahmoudi M, Meyer T. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001;19(20):4054-7.
    367. Prakash P, Cronin CG, Blake MA. Role of PET/CT in ovarian cancer. AJR American journal of roentgenology. 2010;194(6):W464-70.
    368. Miller RE, Rustin GJ. How to follow-up patients with epithelial ovarian cancer. Current opinion in oncology. 2010;22(5):498-502.
    369. Bristow RE, del Carmen MG, Pannu HK, Cohade C, Zahurak ML, Fishman EK, et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecologic oncology. 2003;90(3):519-28.
    370. Palomar A, Nanni C, Castellucci P, Ambrosini V, Montini GC, Allegri V, et al. Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels. Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging. 2012;14(1):123-9.
    371. Fulham MJ, Carter J, Baldey A, Hicks RJ, Ramshaw JE, Gibson M. The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection Project. Gynecologic oncology. 2009;112(3):462-8.
    372. Blackledge G, Lawton F, Redman C, Kelly K. Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. British journal of cancer. 1989;59(4):650-3.
    373. Gore ME, Fryatt I, Wiltshaw E, Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecologic oncology. 1990;36(2):207-11.
    374. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991;9(3):389-93.
    375. Hurteau JA, Brady MF, Darcy KM, McGuire WP, Edmonds P, Pearl ML, et al. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecologic oncology. 2010;119(3):444-50.
    376. Boente MP, Chi DS, Hoskins WJ. The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Seminars in oncology. 1998;25(3):326-34.
    377. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer. 2000;88(1):144-53.
    378. Munkarah AR, Coleman RL. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecologic oncology. 2004;95(2):273-80.
    379. Tebes SJ, Sayer RA, Palmer JM, Tebes CC, Martino MA, Hoffman MS. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecologic oncology. 2007;106(3):482-7.
    380. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361(9375):2099-106.
    381. Galaal K, Naik R, Bristow RE, Patel A, Bryant A, Dickinson HO. Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer. The Cochrane database of systematic reviews. 2010(6):CD007822.
    382. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecologic oncology. 2009;112(1):265-74.
    383. Zang RY, Harter P, Chi DS, Sehouli J, Jiang R, Trope CG, et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. British journal of cancer. 2011;105(7):890-6.
    384. Harter P, Sehouli J, Reuss A, Hasenburg A, Scambia G, Cibula D, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2011;21(2):289-95.
    385. van de Laar R, Zusterzeel PL, Van Gorp T, Buist MR, van Driel WJ, Gaarenstroom KN, et al. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study. BMC cancer. 2014;14:22.
    386. Kolomainen DF, A'Hern R, Coxon FY, Fisher C, King DM, Blake PR, et al. Can patients with relapsed, previously untreated, stage I epithelial ovarian cancer be successfully treated with salvage therapy? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003;21(16):3113-8.
    387. Chan JK, Tian C, Teoh D, Monk BJ, Herzog T, Kapp DS, et al. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecologic oncology. 2010;116(3):307-11.
    388. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001;19(14):3312-22.
    389. Mutch DG, Orlando M, Goss T, Teneriello MG, Gordon AN, McMeekin SD, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(19):2811-8.
    390. Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(6):890-6.
    391. Sehouli J, Stengel D, Oskay-Oezcelik G, Zeimet AG, Sommer H, Klare P, et al. Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(19):3176-82.
    392. ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997;15(6):2183-93.
    393. Rosenberg P, Andersson H, Boman K, Ridderheim M, Sorbe B, Puistola U, et al. Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum. Acta oncologica. 2002;41(5):418-24.
    394. Baird RD, Tan DS, Kaye SB. Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nature reviews Clinical oncology. 2010;7(10):575-82.
    395. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(13):1302-8.
    396. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(29):4699-707.
    397. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(20):3323-9.
    398. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(19):3107-14.
    399. Williams C, Simera I, Bryant A. Tamoxifen for relapse of ovarian cancer. The Cochrane database of systematic reviews. 2010(3):CD001034.
    400. Kristensen G, Kaern J, Baekelandt M, Skeie-Jensensen T, dePont Christensen R, Åvall-Lundqvist E, et al. Chemotherapy versus hormonal treatment in patients with platinum and taxane resistant ovarian cancer: A NSGO study. J Clin Oncol 26: 2008 (May 20 suppl; abstr 5508).
    401. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(17):2039-45.
    402. Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(13):1309-16.
    403. NRPV. Palliativguiden. Stockholm: Nationella Rådet för Palliativ Vård.; 2010
    404. Chan R, Webster J. End-of-life care pathways for improving outcomes in caring for the dying. The Cochrane database of systematic reviews. 2010(1):CD008006.
    405. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. The New England journal of medicine. 2010;363(8):733-42.
    406. Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995;63(1):65-76.
    407. Wiffen PJ, McQuay HJ. Oral morphine for cancer pain. The Cochrane database of systematic reviews. 2007(4):CD003868.
    408. Strang P, Beck-Friis B. Palliativ medicin och vård (under tryckning). 4e rev. upplagan ed. Stockholm: Liber; 2012.
    409. Strang P. Cancerrelaterad smärta. Onkologiska och palliativa aspekter. Lund: Studentlitteratur; 2003.
    410. Davis MP, Hallerberg G, Palliative Medicine Study Group of the Multinational Association of Supportive Care in C. A systematic review of the treatment of nausea and/or vomiting in cancer unrelated to chemotherapy or radiation. Journal of pain and symptom management. 2010;39(4):756-67.
    411. Glare P, Pereira G, Kristjanson LJ, Stockler M, Tattersall M. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2004;12(6):432-40.
    412. Mystakidou K, Befon S, Liossi C, Vlachos L. Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer. Cancer. 1998;83(6):1214-23.
    413. Tuca A, Roca R, Sala C, Porta J, Serrano G, Gonzalez-Barboteo J, et al. Efficacy of granisetron in the antiemetic control of nonsurgical intestinal obstruction in advanced cancer: a phase II clinical trial. Journal of pain and symptom management. 2009;37(2):259-70.
    414. Bruera E, Moyano JR, Sala R, Rico MA, Bosnjak S, Bertolino M, et al. Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. Journal of pain and symptom management. 2004;28(4):381-8.
    415. Feuer DJ, Broadley KE. Systematic review and meta-analysis of corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancers. Systematic Review Steering Committee. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 1999;10(9):1035-41.
    416. Tunca JC, Buchler DA, Mack EA, Ruzicka FF, Crowley JJ, Carr WF. The management of ovarian-cancer-caused bowel obstruction. Gynecologic oncology. 1981;12(2 Pt 1):186-92.
    417. Sartori E, Chiudinelli F, Pasinetti B, Maggino T. Bowel obstruction and survival in patients with advanced ovarian cancer: analysis of prognostic variables. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009;19(1):54-7.
    418. Pothuri B, Montemarano M, Gerardi M, Shike M, Ben-Porat L, Sabbatini P, et al. Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecologic oncology. 2005;96(2):330-4.
    419. Dolan EA. Malignant bowel obstruction: a review of current treatment strategies. The American journal of hospice & palliative care. 2011;28(8):576-82.
    420. Kucukmetin A, Naik R, Galaal K, Bryant A, Dickinson HO. Palliative surgery versus medical management for bowel obstruction in ovarian cancer. The Cochrane database of systematic reviews. 2010(7):CD007792.
    421. Krebs HB, Goplerud DR. The role of intestinal intubation in obstruction of the small intestine due to carcinoma of the ovary. Surgery, gynecology & obstetrics. 1984;158(5):467-71.
    422. Hope JM, Pothuri B. The role of palliative surgery in gynecologic cancer cases. The oncologist. 2013;18(1):73-9.
    423. Good P, Cavenagh J, Mather M, Ravenscroft P. Medically assisted hydration for palliative care patients. The Cochrane database of systematic reviews. 2008(2):CD006273.
    424. Good P, Cavenagh J, Mather M, Ravenscroft P. Medically assisted nutrition for palliative care in adult patients. The Cochrane database of systematic reviews. 2008(4):CD006274.
    425. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. The Lancet Oncology. 2011;12(5):489-95
    426. Woopen H, Sehouli J. Current and future options in the treatment of malignant ascites in ovarian cancer. Anticancer research. 2009;29(8):3353-9
    427. Link KH, Roitman M, Holtappels M, Runnebaum I, Urbanzyk H, Leder G, et al. Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. Surgical oncology clinics of North America. 2003;12(3):865-72, xvi-xvii
    428. Marinaccio M, Mele E, De Marino E, Catacchio R, Pellegrino C, Sozzi F, S. Schonauer S. Intraperitoneal mitoxantrone in the treatment of recurrent ascites from progressive epithelial ovarian cancer.J Clin Oncol 28:15s, 2010 (suppl; abstr 5051).
    429. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. International journal of cancer Journal international du cancer. 2010;127(9):2209-21.
    430. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. The American journal of pathology. 2004;164(5):1511-8.
    431. Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. The American journal of surgical pathology. 2005;29(2):218-24.
    432. Skirnisdottir I, Garmo H, Wilander E, Holmberg L. Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. International journal of cancer Journal international du cancer. 2008;123(8):1897-901.
    433. Yarandi F, Eftekhar Z, Izadi-Mood N, Shojaei H. Accuracy of intraoperative frozen section in the diagnosis of ovarian tumors. The Australian & New Zealand journal of obstetrics & gynaecology. 2008;48(4):438-41.
    434. Akeson M, Zetterqvist BM, Dahllof K, Jakobsen AM, Brannstrom M, Horvath G. Population-based cohort follow-up study of all patients operated for borderline ovarian tumor in western Sweden during an 11-year period. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2008;18(3):453-9.
    435. Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Human pathology. 2000;31(5):539-57.
    436. Ren J, Peng Z, Yang K. A clinicopathologic multivariate analysis affecting recurrence of borderline ovarian tumors. Gynecologic oncology. 2008;110(2):162-7.
    437. Lenhard MS, Mitterer S, Kumper C, Stieber P, Mayr D, Ditsch N, et al. Long-term follow-up after ovarian borderline tumor: relapse and survival in a large patient cohort. European journal of obstetrics, gynecology, and reproductive biology. 2009;145(2):189-94.
    438. Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up. The American journal of surgical pathology. 2005;29(6):707-23.
    439. Trillsch F, Mahner S, Ruetzel J, Harter P, Ewald-Riegler N, Jaenicke F, et al. Clinical management of borderline ovarian tumors. Expert review of anticancer therapy. 2010;10(7):1115-24.
    440. du Bois A, Ewald-Riegler N, du Bois O, Harter P. Borderline tumors of the ovary – a systematic review [German]. Geburtsh Frauenheilk 2009;69, 807–833. .
    441. Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Mangioni C. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001;19(10):2658-64.
    442. Kaern J, Trope CG, Kristensen GB, Abeler VM, Pettersen EO. DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 1993;3(6):349-58.
    443. Trope C, Davidson B, Paulsen T, Abeler VM, Kaern J. Diagnosis and treatment of borderline ovarian neoplasms "the state of the art". European journal of gynaecological oncology. 2009;30(5):471-82.
    444. Verbruggen MB, van Diest PJ, Baak JP, Broeckaert MA, Kenemans P, Verheijen RH. The prognostic and clinical value of morphometry and DNA cytometry in borderline ovarian tumors: a prospective study. International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 2009;28(1):35-40.
    445. Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(20):2928-37.
    446. Faluyi O, Mackean M, Gourley C, Bryant A, Dickinson HO. Interventions for the treatment of borderline ovarian tumours. The Cochrane database of systematic reviews. 2010(9):CD007696.
    447. Fischerova D, Zikan M, Dundr P, Cibula D. Diagnosis, treatment, and follow-up of borderline ovarian tumors. The oncologist. 2012;17(12):1515-33.
    448. Sherman ME, Mink PJ, Curtis R, Cote TR, Brooks S, Hartge P, et al. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer. 2004;100(5):1045-52.
    449. Song T, Hun Choi C, Lee YY, Kim TJ, Lee JW, Bae DS, et al. Oncologic and reproductive outcomes of cystectomy compared with oophorectomy as a treatment for borderline ovarian tumours. Human reproduction. 2011;26(8):2008-14.
    450. Einhorn N. Kemoterapi och effekter på gonaderna;  Hormonell ovarialstimulering för infertilitetsbehandling och risk för ovarialcancer. Högberg T., Larsson B (red.). Cancer, graviditet och fertilitet. ARG-rapport nr 41. Stockholm: Svensk förening för obstetrik och gynekologi 1999.
    451. Pentheroudakis G, Orecchia R, Hoekstra HJ, Pavlidis N, Group EGW. Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2010;21 Suppl 5:v266-73.
    452. Koyama H, Wada T, Nishizawa Y, Iwanaga T, Aoki Y. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer. 1977;39(4):1403-9.
    453. Del Mastro L, Ceppi M, Poggio F, Bighin C, Peccatori F, Demeestere I, et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer treatment reviews. 2014;40(5):675-83.
    454. Brynhildsen J, Wikström I. Preventivmedel och cancer. Information från Läkemedelsverket 2: 2014.  .
    455. Wong M, O'Neill S, Walsh G, Smith IE. Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013;24(1):133-8.
    456. Valentin J. (red.). Pregnancy and medical radiation. Annals of the ICRP 2000;30:1–43. Oxford, Pergamon press.
    457. Nyman U, Bajc M, Eriksson H, Geijer H, Gunnarsson M, Hellgren M, et al. [Diagnosis of pulmonary embolism in pregnant women. Scintigraphy or computer tomography?]. Lakartidningen. 2010;107(15):989-94.
    458. Lindqvist PG, Leidner B, Aspelin P. [Diagnosis of suspected pulmonary embolism in pregnant women. We recommend CT of pulmonary arteries before scintigraphy]. Lakartidningen. 2010;107(40):2413-4; discussion 5-6.
    459. Webb JA, Thomsen HS, Morcos SK, Members of Contrast Media Safety Committee of European Society of Urogenital R. The use of iodinated and gadolinium contrast media during pregnancy and lactation. European radiology. 2005;15(6):1234-40.
    460. Pavlidis NA. Coexistence of pregnancy and malignancy. The oncologist. 2002;7(4):279-87.
    461. Bernhard LM, Klebba PK, Gray DL, Mutch DG. Predictors of persistence of adnexal masses in pregnancy. Obstetrics and gynecology. 1999;93(4):585-9.
    462. Giuntoli RL, 2nd, Vang RS, Bristow RE. Evaluation and management of adnexal masses during pregnancy. Clinical obstetrics and gynecology. 2006;49(3):492-505.
    463. Peccatori FA, Azim HA, Jr., Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013;24 Suppl 6:vi160-70.
    464. Han SN, Lotgerink A, Gziri MM, Van Calsteren K, Hanssens M, Amant F. Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review. BMC medicine. 2012;10:86.
    465. Leiserowitz GS. Managing ovarian masses during pregnancy. Obstetrical & gynecological survey. 2006;61(7):463-70.
    466. Amant F, Van Calsteren K, Halaska MJ, Beijnen J, Lagae L, Hanssens M, et al. Gynecologic cancers in pregnancy: guidelines of an international consensus meeting. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009;19 Suppl 1:S1-12.
    467. Cohen-Kerem R, Railton C, Oren D, Lishner M, Koren G. Pregnancy outcome following non-obstetric surgical intervention. American journal of surgery. 2005;190(3):467-73.
    468. Marret H, Lhomme C, Lecuru F, Canis M, Leveque J, Golfier F, et al. Guidelines for the management of ovarian cancer during pregnancy. European journal of obstetrics, gynecology, and reproductive biology. 2010;149(1):18-21.
    469. Jansen FW, Kolkman W, Bakkum EA, de Kroon CD, Trimbos-Kemper TC, Trimbos JB. Complications of laparoscopy: an inquiry about closed- versus open-entry technique. American journal of obstetrics and gynecology. 2004;190(3):634-8.
    470. Childers JM, Brzechffa PR, Surwit EA. Laparoscopy using the left upper quadrant as the primary trocar site. Gynecologic oncology. 1993;50(2):221-5.
    471. Ngu SF, Cheung VY, Pun TC. Left upper quadrant approach in gynecologic laparoscopic surgery. Acta obstetricia et gynecologica Scandinavica. 2011;90(12):1406-9.
    472. Fauvet R, Brzakowski M, Morice P, Resch B, Marret H, Graesslin O, et al. Borderline ovarian tumors diagnosed during pregnancy exhibit a high incidence of aggressive features: results of a French multicenter study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2012;23(6):1481-7.
    473. Van Calsteren K, Heyns L, De Smet F, Van Eycken L, Gziri MM, Van Gemert W, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(4):683-9.
    474. Dekrem J, Van Calsteren K, Amant F. Effects of fetal exposure to maternal chemotherapy. Paediatric drugs. 2013;15(5):329-34.
    475. Lindmark G. Läkemedelsbehandling under graviditet. I Obstetrisk öppenvård. Red. Marsal, Grennert Liber 2004; 91-101.
    476. Tholander B. Cancer och graviditet. I Obstetrisk öppenvård. Red. Marsal, Grennert Liber 2004; 161-172.
    477. Calsteren KV, Verbesselt R, Devlieger R, De Catte L, Chai DC, Van Bree R, et al. Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2010;20(9):1456-64.
    478. Berveiller P, Veyrie N, Rouzier R, Carbonne B, Mir O. Anti-cancer agents for breast cancer treatment during pregnancy. Journal of surgical oncology. 2011;104(5):560; author reply 59.
    479. Raffles A, Williams J, Costeloe K, Clark P. Transplacental effects of maternal cancer chemotherapy. Case report. British journal of obstetrics and gynaecology. 1989;96(9):1099-100.
    480. Mir O, Berveiller P, Goffinet F, Treluyer JM, Serreau R, Goldwasser F, et al. Taxanes for breast cancer during pregnancy: a systematic review. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2010;21(2):425-6.
    481. Amant F, Van Calsteren K, Halaska MJ, Gziri MM, Hui W, Lagae L, et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. The Lancet Oncology. 2012;13(3):256-64.
    482. Van Calsteren K, Berteloot P, Hanssens M, Vergote I, Amant F, Ganame J, et al. In utero exposure to chemotherapy: effect on cardiac and neurologic outcome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(12):e16-7.
    483. Ring AE, Smith IE, Jones A, Shannon C, Galani E, Ellis PA. Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005;23(18):4192-7.
    484. Kew F, Galaal K, Bryant A, Naik R. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment. The Cochrane database of systematic reviews. 2011(6):CD006119.
    485. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376(9747):1155-63.
    486. Aebi S, Castiglione M, Group EGW. Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2008;19 Suppl 2:ii14-6.
    487. Gadducci A, Fuso L, Cosio S, Landoni F, Maggino T, Perotto S, et al. Are surveillance procedures of clinical benefit for patients treated for ovarian cancer?: A retrospective Italian multicentric study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009;19(3):367-74
    488. Geurts SM, van Altena AM, de Vegt F, Tjan-Heijnen VC, Massuger LF, van Dijck JA, et al. No supportive evidence for clinical benefit of routine follow-up in ovarian cancer: a Dutch multicenter study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2011;21(4):647-53.
    489. Forstner R, Sala E, Kinkel K, Spencer JA, European Society of Urogenital R. ESUR guidelines: ovarian cancer staging and follow-up. European radiology. 2010;20(12):2773-80.
    490. Kew FM, Galaal K, Manderville H. Patients' views of follow-up after treatment for gynaecological cancer. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. 2009;29(2):135-42.
    491. Papagrigoriadis S, Heyman B. Patients' views on follow up of colorectal cancer: implications for risk communication and decision making. Postgraduate medical journal. 2003;79(933):403-7.
    492. Vistad I, Cvancarova M, Salvesen HB. Follow-up of gynecological cancer patients after treatment - the views of European experts in gynecologic oncology. Acta obstetricia et gynecologica Scandinavica. 2012;91(11):1286-92.
    493. Cox A, Bull E, Cockle-Hearne J, Knibb W, Potter C, Faithfull S. Nurse led telephone follow up in ovarian cancer: a psychosocial perspective. European journal of oncology nursing : the official journal of European Oncology Nursing Society. 2008;12(5):412-7.
    494. Anchezar JP, Sardi J, Soderini A. Long-term follow-up results of fertility sparing surgery in patients with epithelial ovarian cancer. Journal of surgical oncology. 2009;100(1):55-8.
    495. Borgfeldt C, Iosif C, Masback A. Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer. European journal of obstetrics, gynecology, and reproductive biology. 2007;134(1):110-4.
    496. Schlaerth AC, Chi DS, Poynor EA, Barakat RR, Brown CL. Long-term survival after fertility-sparing surgery for epithelial ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009;19(7):1199-204.
    497. www.nccn.org/professionals/physician_gls/f_guidelines.asp.
    498. King J, Wynne CH, Assersohn L, Jones A. Hormone replacement therapy and women with premature menopause--a cancer survivorship issue. European journal of cancer. 2011;47(11):1623-32.
    499. Jacoby VL, Grady D, Sawaya GF. Oophorectomy as a risk factor for coronary heart disease. American journal of obstetrics and gynecology. 2009;200(2):140 e1-9.
    500. Rivera CM, Grossardt BR, Rhodes DJ, Brown RD, Jr., Roger VL, Melton LJ, 3rd, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause. 2009;16(1):15-23.
    501. Hopkins ML, Fung MF, Le T, Shorr R. Ovarian cancer patients and hormone replacement therapy: a systematic review. Gynecologic oncology. 2004;92(3):827-32.
    502. Guidozzi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial. Cancer. 1999;86(6):1013-8.
    503. Eeles RA, Tan S, Wiltshaw E, Fryatt I, A'Hern RP, Shepherd JH, et al. Hormone replacement therapy and survival after surgery for ovarian cancer. Bmj. 1991;302(6771):259-62.
    504. Mascarenhas C, Lambe M, Bellocco R, Bergfeldt K, Riman T, Persson I, et al. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. International journal of cancer Journal international du cancer. 2006;119(12):2907-15.
    505. Loprinzi CL, Barton DL, Qin R. Nonestrogenic management of hot flashes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(29):3842-6.
    506. Dodin S, Blanchet C, Marc I, Ernst E, Wu T, Vaillancourt C, et al. Acupuncture for menopausal hot flushes. The Cochrane database of systematic reviews. 2013;7:CD007410.
    507. Daley A, Stokes-Lampard H, Macarthur C. Exercise for vasomotor menopausal symptoms. The Cochrane database of systematic reviews. 2011(5):CD006108.
    508. Ramos SM, O'Donnell LS, Knight G. Edema volume, not timing, is the key to success in lymphedema treatment. American journal of surgery. 1999;178(4):311-5.
    509. McNeely ML, Peddle CJ, Yurick JL, Dayes IS, Mackey JR. Conservative and dietary interventions for cancer-related lymphedema: a systematic review and meta-analysis. Cancer. 2011;117(6):1136-48.
    510. Rodrick JR, Poage E, Wanchai A, Stewart BR, Cormier JN, Armer JM. Complementary, alternative, and other noncomplete decongestive therapy treatment methods in the management of lymphedema: a systematic search and review. PM & R : the journal of injury, function, and rehabilitation. 2014;6(3):250-74; quiz 74.
    511. McLaughlin SA, Wright MJ, Morris KT, Sampson MR, Brockway JP, Hurley KE, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(32):5220-6.
    512. Speck RM, Courneya KS, Masse LC, Duval S, Schmitz KH. An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. Journal of cancer survivorship : research and practice. 2010;4(2):87-100.
    513. Kwan Ml, Cohn JC, Armer JM et al. Exercise in patients with lymphoedema. a systematic review of the contemporary literature. J Cancer Surviv.2011;5(4):320-336.
    514. Brorsson AC, Lundqvist M, Sethson I, Jonsson BH. GuHCl and NaCl-dependent hydrogen exchange in MerP reveals a well-defined core with an unusual exchange pattern. Journal of molecular biology. 2006;357(5):1634-46.
    515. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(18):1941-67.
    516. Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. Jama. 2013;309(13):1359-67.
    517. Sekse RJ, Hufthammer KO, Vika ME. Fatigue and quality of life in women treated for various types of gynaecological cancers: a cross-sectional study. Journal of clinical nursing. 2014.
    518. Mishra SI, Scherer RW, Snyder C, Geigle PM, Berlanstein DR, Topaloglu O. Exercise interventions on health-related quality of life for people with cancer during active treatment. The Cochrane database of systematic reviews. 2012;8:CD008465.
    519. Jayde V, Boughton M, Blomfield P. The experience of chemotherapy-induced alopecia for Australian women with ovarian cancer. European journal of cancer care. 2013;22(4):503-12.
    520. SBU. Nedkylning av hårbotten för att förhindra håravfall i samband med cytostatikabehandling. Stockholm: Statens beredning för medicinsk utvärdering (SBU); 2005. SBU Alert-rapport nr 2005-06. ISSN 1652-7151
    521. von Moos R, Thuerlimann BJ, Aapro M, Rayson D, Harrold K, Sehouli J, et al. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. European journal of cancer. 2008;44(6):781-90.
    522. Macedo LT, Lima JP, dos Santos LV, Sasse AD. Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2014;22(6):1585-93.
    523. Janelsins MC, Kohli S, Mohile SG, Usuki K, Ahles TA, Morrow GR. An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Seminars in oncology. 2011;38(3):431-8.
    524. Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nature reviews Cancer. 2008;8(11):887-99.
    525. Basson R. Sexual function of women with chronic illness and cancer. Women's health. 2010;6(3):407-29.
    526. Ratner ES, Foran KA, Schwartz PE, Minkin MJ. Sexuality and intimacy after gynecological cancer. Maturitas. 2010;66(1):23-6.
    527. Bloom JR, Petersen DM, Kang SH. Multi-dimensional quality of life among long-term (5+ years) adult cancer survivors. Psycho-oncology. 2007;16(8):691-706.
    528. Pilger A, Richter R, Fotopoulou C, Beteta C, Klapp C, Sehouli J. Quality of life and sexuality of patients after treatment for gynaecological malignancies: results of a prospective study in 55 patients. Anticancer research. 2012;32(11):5045-9.
    529. Stewart DE, Wong F, Duff S, Melancon CH, Cheung AM. "What doesn't kill you makes you stronger": an ovarian cancer survivor survey. Gynecologic oncology. 2001;83(3):537-42.
    530. Carmack Taylor CL, Basen-Engquist K, Shinn EH, Bodurka DC. Predictors of sexual functioning in ovarian cancer patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004;22(5):881-9.
    531. Liavaag AH, Dorum A, Bjoro T, Oksefjell H, Fossa SD, Trope C, et al. A controlled study of sexual activity and functioning in epithelial ovarian cancer survivors. A therapeutic approach. Gynecologic oncology. 2008;108(2):348-54.
    532. Bodurka DC, Sun CC. Sexual function after gynecologic cancer. Obstetrics and gynecology clinics of North America. 2006;33(4):621-30, ix.
    533. Stead ML, Brown JM, Fallowfield L, Selby P. Lack of communication between healthcare professionals and women with ovarian cancer about sexual issues. British journal of cancer. 2003;88(5):666-71.
    534. Basson R. Using a different model for female sexual response to address women's problematic low sexual desire. Journal of sex & marital therapy. 2001;27(5):395-403.
    535. Gilbert E, Ussher JM, Perz J. Sexuality after gynaecological cancer: a review of the material, intrapsychic, and discursive aspects of treatment on women's sexual-wellbeing. Maturitas. 2011;70(1):42-57.
    536. Morreale MK. The impact of cancer on sexual function. Balon R (ed):sexual dysfunction:beyond the brain-body connection. Adv Psychosom Med. Basel,Karger,2011.vol 31:72-82.
    537. Serretti A and Chiesa A. Treatment-emergent sexual dysfunction retlated to antidepressants. A meta –analysis. J Clin Psychopharmacology 2009;vol 29, 3: 259-266.  .
    538. Salonia A, Briganti A, Deho F, Zanni G, Rigatti P, Montorsi F. Women's sexual dysfunction: a review of the "surgical landscape". European urology. 2006;50(1):44-52.
    539. Havenga K, Maas CP, DeRuiter MC, Welvaart K, Trimbos JB. Avoiding long-term disturbance to bladder and sexual function in pelvic surgery, particularly with rectal cancer. Seminars in surgical oncology. 2000;18(3):235-43.
    540. Maas CP, ter Kuile MM, Laan E, Tuijnman CC, Weijenborg PT, Trimbos JB, et al. Objective assessment of sexual arousal in women with a history of hysterectomy. BJOG : an international journal of obstetrics and gynaecology. 2004;111(5):456-62.
    541. Ibeanu O, Modesitt SC, Ducie J, von Gruenigen V, Agueh M, Fader AN. Hormone replacement therapy in gynecologic cancer survivors: why not? Gynecologic oncology. 2011;122(2):447-54.
    542. Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. The Journal of clinical endocrinology and metabolism. 2005;90(7):3847-53.
    543. Nathorst-Boos J, von Schoultz B. Psychological reactions and sexual life after hysterectomy with and without oophorectomy. Gynecologic and obstetric investigation. 1992;34(2):97-101.
    544. Davis SR. Androgen use for low sexual desire in midlife women. Menopause. 2013;20(7):795-7.
    545. Bachmann G, Bancroft J, Braunstein G, Burger H, Davis S, Dennerstein L, et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertility and sterility. 2002;77(4):660-5.
    546. Carter J, Chi DS, Brown CL, Abu-Rustum NR, Sonoda Y, Aghajanian C, et al. Cancer-related infertility in survivorship. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2010;20(1):2-8.
    547. Carter J, Goldfrank D, Schover LR. Simple strategies for vaginal health promotion in cancer survivors. The journal of sexual medicine. 2011;8(2):549-59.
    548. Audette C, Waterman J. The sexual health of women after gynecologic malignancy. Journal of midwifery & women's health. 2010;55(4):357-62.
    549. Annon J. The PLISSIT model: a proposed conceptual scheme for the behavioural treatment of sexual problems. J Sex Edu Ther. 1976;2:1-15.
    550. Lamont J, Society of O, Gynaecologists of C. Female sexual health consensus clinical guidelines. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC. 2012;34(8):769-83.
    551. Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, et al. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). Journal of the National Cancer Institute. 2004;96(6):487-8.
    552. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2011;21(2):419-23.